BTS 71321

Drug Profile

BTS 71321

Latest Information Update: 26 Nov 2004

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Boots Pharmaceuticals
  • Class Anti-inflammatories; Antiasthmatics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Asthma; Skin disorders

Most Recent Events

  • 31 Dec 2002 Discontinued - Phase-II for Asthma in United Kingdom (PO)
  • 31 Dec 2002 Discontinued - Preclinical for Skin disorders in United Kingdom (Topical)
  • 29 Oct 1999 BTS 71321 is available for licensing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top